|
Kheiron Medical
Technologies partners with
Medtech Corporation to bring
AI breast screening solution
to Qatar
(Doha, Qatar) -
Mia®, a deep learning
artificial intelligence (AI)
solution that works with
radiologists to improve
breast cancer detection,
avoid unnecessary biopsies
and ultimately improve the
patient experience for all
women is being launched in
Qatar.
UK-based
Kheiron Medical
Technologies has signed an
agreement with Medtech
Corporation in Qatar, a
supplier of medical and
laboratory equipment, to
bring its Mia solution to
the Qatar market. With
patented AI technology
developed on more than three
million breast images, Mia
(Mammography Intelligent
Assessment) is designed to
support breast radiologists
in making the critical
decision to recall women for
further testing based on
their mammography screening.
Mia is the first solution of
its kind to receive the CE
(European regulatory
clearance) mark for use as
an AI-enabled independent
reader for the detection of
breast cancer. Through
rigorous clinical studies
and testing, Mia has learnt
to read mammograms to the
same level of detail as a
consulting radiologist.
In
double-reading mammography
workflows where scans are
reviewed by two
radiologists, Mia can be
deployed independently
alongside a single human
reader. This delivers the
quality improvements needed
to ensure the sustainability
of breast screening services
and frees up clinicians to
spend more time with
patients. Mia can also be
deployed as a concurrent
reader or in double reader
triage.
Her Majesty’s Trade
Commissioner for the Middle
East, Simon Penney, added:
“I am delighted that Kheiron
Medical Technologies is
bringing their breakthrough
AI platform for breast
screening, Mia, to the Gulf
region, and that the UK’s
Department for International
Trade played a role in
making this happen.
Kheiron’s technology brings
pioneering artificial
intelligence to the
frontline, freeing up
clinicians’ time and helping
to save lives.”
Speaking at a signing
ceremony between Kheiron and
Medtech Corporation, Alex
Hamlow, Kheiron’s Chief
Commercial Officer, said;
“Our mission at Kheiron is
to support breast screening
professionals in the fight
against breast cancer with
proven and effective
AI-enabled tools. We’re
excited that Mia is the
first AI independent reader
solution available for use
within the breast screening
community in Qatar. Based on
its performance in the UK
and Europe, Mia represents a
major breakthrough in
helping radiologists to
dramatically improve breast
cancer detection and patient
outcomes.
“According to the WHO’s
International Agency for
Research on Cancer, breast
cancer was the most
prevalent of all cancers
detected in Qatar in 2020,
accounting for 37.5% of all
new cancer cases detected in
women. I’m excited that Mia
can help both radiologists
and the women they care
for,” Mr Hamlow continued.
“We are looking forward to
bringing Kheiron’s Mia
solution to Qatar’s breast
screening community,”
comments Dr. Hassan Kunhi,
Chief Executive Officer for
Medtech. “Like Kheiron, we
are driven by a desire to
achieve the highest quality
in everything we do. Mia has
tremendous potential to
improve radiologist
productivity and empower
breast screening
professionals to detect
potential malignancies more
accurately and quickly. This
means that Mia ultimately
will help save more lives in
the fight against breast
cancer.”
Mia’s effectiveness has been
proven in one of the most
ambitious clinical studies
in radiology AI to date and
tested across multiple
demographics and mammography
devices. It was one of the
recipients of the UK
Government’s first AI in
Health and Care Awards
through which Mia is
undergoing multiple
deployments and clinical
studies across 15 sites in
the UK as a benchmark for
how to integrate new,
cutting edge technologies
into the NHS safely and
effectively. Kheiron and AI
Advance are currently
working with an Australian
breast-screening provider to
establish the protocols for
a forthcoming clinical
trial, details of which will
soon be announced.
Mia will be available to the
UAE, Qatar and Oman markets
pending local requirements.
PRINT
THIS ARTICLE
|